Fennec Pharmaceuticals Inc.
FENC
$6.01
-$0.27-4.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 25.99% | -207.18% | -2.00% | 312.11% | 60.89% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 1,178.57% | -70.83% | -68.49% | -72.22% | 0.00% |
| Total Other Non-Cash Items | 92.05% | 301.67% | -47.70% | 42.98% | -80.77% |
| Change in Net Operating Assets | 102.15% | -9.64% | -276.83% | 3,433.38% | -160.65% |
| Cash from Operations | 69.67% | 20.07% | -112.54% | 800.14% | 28.55% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | 2,790.17% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6.69% | -- | -35.86% | 194.37% | 10.01% |
| Repurchase of Common Stock | 47.06% | -3,671.43% | -233.33% | 5.00% | 39.29% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -313.12% | -362.69% | -50.00% | -686.53% | 595.39% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,673.10% | -6.84% | -136.89% | 804.22% | 114.55% |